We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00749580
Recruitment Status : Completed
First Posted : September 9, 2008
Results First Posted : July 22, 2014
Last Update Posted : December 17, 2014
Information provided by (Responsible Party):

September 5, 2008
September 9, 2008
March 27, 2014
July 22, 2014
December 17, 2014
November 2008
July 2011   (Final data collection date for primary outcome measure)
Number of Patients With Suppressed Viral Load(<75 Copies/ml)in Raltegravir 400 mg Bid vs. NRTI Backbone, Each in Combination of Boosted PI Regimen [ Time Frame: at 24weeks for each patient ]
Number of patients with virologic suppression< 75 copies/ ml at 24 wk,in raltegravir 400 mg bid vs. NRTI backbone, each in combination of boosted PI regimen.
The purpose of this study is to evaluate the safety and tolerability of raltegravir 400 mg b.i.d. compared with the NRTI backbone group, each in combination with a boosted PI regimen, as assessed by a review of the accumulated safety data at Week 24. [ Time Frame: 24 weeks for each patient ]
Complete list of historical versions of study NCT00749580 on ClinicalTrials.gov Archive Site
Virologic Suppression of < 75 Copies/ml at 48 Weeks [ Time Frame: at 48 weeks for each patient ]
Not Provided
Not Provided
Not Provided
A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen
A Pilot, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Raltegravir Versus NRTIs as a Backbone in HIV-Infected Patients Switched From a Stable Boosted PI Regimen
The purpose of this study is to determine whether raltegravir 400 mg b.i.d. in a boosted PI regimen is as efficacious and safe as the NRTI backbone in a boosted PI regimen.
Not Provided
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Virus Diseases
  • HIV
Drug: Switch NRTIs as a Backbone to Raltegravir
This is a multicenter, pilot randomized, controlled study to evaluate the safety and efficacy of raltegravir in patients switched from a stable boosted PI-based regimen with a NRTI backbone to raltegravir instead of their current NRTIs. A stable boosted PI-based regimen is defined as having a documented HIV RNA <75 copies/mL for ≥ 3 months prior to study entry, while receiving a boosted PI-based with NRTI backbone. Additionally, patients must not have had HIV RNA ≥ 75 copies/mL during the three months prior to study entry. Approximately 25 patients will be enrolled in the raltegravir treatment arm (Group 1) and approximately 25 patients in the continuation of the current NRTI backbone regimen treatment arm (Group 2). Patients will be randomly assigned 1:1 to a treatment group.
  • Experimental: 1: Boosted PI+RAL
    Group 1 Raltegravir 400 mg PO b.i.d. + their current boosted PI regimen Subjects in this study are HIV-Infected Patients who are on a stable boosted PI regimen; in this group are assigned to switched from their NRTIs as a Backbone to Raltegravir
    Intervention: Drug: Switch NRTIs as a Backbone to Raltegravir
  • No Intervention: 2: Boosted PI+NRTIs
    Group 2 Continue the same regimen without change
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
July 2011
July 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patient is a male or female at least 18 years of age on the day of signing the informed consent.
  2. Patient is HIV positive as determined by enzyme-linked immunosorbent assay (ELISA) or HIV PCR.
  3. Patient has documented HIV RNA <75 copies/mL for at least 3 months prior to study entry while on a stable boosted PI based regimen without a change in antiretroviral therapy and with no documentation of HIV RNA > or = 75 copies/mL during this time.
  4. Patient has no history of documented coronary artery disease that clinical investigator deems as clinically significant.
  5. Patient has the following laboratory values within 35 days prior to the treatment phase of this study:

    • Alkaline phosphatase ≤ 5.0 x upper limit of normal
    • AST (SGOT) and ALT (SGPT) ≤ 5.0 x upper limit of normal. Patients with Hepatitis C Coinfection may be enrolled provided the patients are stable and meet all eligibility criteria.
  6. Patient has no clinical evidence of active pulmonary disease; at the investigators, discretion a chest x-ray could be obtained if felt necessary.
  7. Patient who is of reproductive potential agrees to use an acceptable method of birth control throughout the study.
  8. Patient agrees to remain off prohibited concomitant medications as outlined in Section 3.2.1 of the protocol.

Exclusion Criteria:

  1. Patients who are currently failing a boosted PI based regimen.
  2. Patient is receiving a second line boosted PI regimen including boosted tripranavir or boosted darunavir.
  3. Patients with chronic hepatitis B infection.
  4. Patient has a history or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the patient's participation for the full duration of the study, such that it is not in the best interest of the patient to participate.
  5. Patient has a history of alcohol or other substance abuse that in the opinion of the investigator would interfere with patient compliance or safety.
  6. Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent.
  7. Patient has ever used any experimental HIV-integrase inhibitor.
  8. Patient has used systemic immunosuppressive therapy (e.g., 20 mg or more of prednisone or equivalent per day) within one month prior to treatment in this study. Short courses of corticosteroids (e.g., as for asthma exacerbation) will be allowed.
  9. Patient requires hemodialysis.
  10. Patient has significant hypersensitivity or other contraindication to any of the components of the study drugs.
  11. Patient has chronic hepatitis, including chronic hepatitis B and/or C and has decompensated liver disease.
  12. Patient is pregnant or breastfeeding, or expecting to conceive (within the duration of the study). Patient is expecting to donate eggs (within the duration of the study). Patient is expecting to donate sperm (within the duration of the study).
  13. Subjects who have received investigational medications within 30 days of baseline.
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
University of South Florida
University of South Florida
  • Merck Sharp & Dohme Corp.
  • St. Joseph's Hospital, Florida
Not Provided
University of South Florida
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP